Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy

Table 1 Incidence of upper gastrointestinal events in low-dose aspirin users

Ref.	Subjects	GI event	Incidence rate
Yeomans et al[12]	187	Gastroduodenal	10.7%
		Gastroduodenal	63.1%
Ishikawa et al[13]	1657	Gastroduodenal	2.65 (95%CI: 2.56-2.74) per 1000 patient years
Niv et al[14]	46 asymptomatic	Gastroduodenal ulcer or erosion	47.83%
Taha et al[17]	200	Gastroduodenal ulcer	23.5%
Scheiman et al[18]	2426 high risk	Gastroduodenal ulcer	7.4%
Sugano et al[19]	235 with a history of ulcer	Gastroduodenal ulcer	31.7%
Serrano et al[9]	903	Upper GI bleeding	1.2 per 100 patient years
Sorensen et al[10]	27  694	Upper GI bleeding	2.6 (95%CI: 2.2-2.9)
Nema et al[15]	101	Gastroduodenal mucosal injury	61.4%
		Gastroduodenal ulcer	18.8%
Nema et al[16]	190	Gastroduodenal mucosal defects	48.4%

GI: Gastrointestinal.

Table 2 Prevention of low-dose aspirin-induced gastroduodenal events

Ref.	Co-treatment	GI event	Incidence rate
Taha et al[17]	Famotidine 40 mg vs placebo	Gastric ulcers/duodenal ulcers	3.4% vs 15.0%
			0.5% vs 8.5%
Scheiman et al[18]	Esomeprazole 40 mg vs 20 mg vs placebo	Gastroduodenal ulcers	1.5% vs 1.1% vs 7.4%
Sugano et al[19]	Lansoprazole 15 mg vs placebo	Gastroduodenal ulcers	3.7% vs 31.7%
Yeomans et al[47]	Esomeprazole 20 mg vs placebo	Gastroduodenal ulcers	1.6% vs 5.4%
Ng et al[50]	Famotidine 40 mg vs pantoprazole 20 mg	Dyspeptic or bleeding ulcers/erosions	20% vs 0%
Chan et al[67]	Omeprazole 20 mg vs H. pylori eradication	Gastroduodenal bleeding	0.9% vs 1.9%
Lai et al[68]	H. pylori eradication + lansoprazole 15 mg vs H. pylori eradication	Gastroduodenal ulcers	1.6% vs 14.8%

GI: Gastrointestinal; H. pylori: Helicobacter pylori.